痛风中的全身炎症和治疗到注的尿酸降低疗法的影响
Austin M Wheeler1,2, Tanner J Ourada1,2, Spencer Q Jones1,2
1VA Nebraska-Western Iowa Health Care System, Omaha, NE.
Rheumatology (Oxford, England)
|December 14, 2025
概括
患有痛风的个人表现出不同的炎症生物标志物模式. 有效的尿酸降低疗法 (ULT) 随着时间的推移显著降低了这些炎症标志物,接近非痛风对照中的水平.
科学领域:
- 风湿病学和免疫学
- 生物标志物发现发现
- 系统性炎症研究 系统性炎症研究
背景情况:
- 痛风与全身性炎症有关,由循环炎症生物标志物表明.
- 有效的尿酸降低疗法 (ULT) 对痛风患者这些全身炎症模式的影响尚未完全理解.
研究的目的:
- 为了确定不同的循环炎症生物标志物模式是否能使患有痛风的个体与没有痛风的对照区分开来.
- 调查高效的尿酸降低疗法 (ULT) 是否会随着时间的推移减轻这些生物标志物差异.
主要方法:
- 使用了病例控制和纵向队列研究设计.
- 来自痛风患者和非痛风对照者的血清样本被分析为20个预先选择的炎症和心脏代谢生物标志物.
- 主要成分分析 (PCA) 和概括估计方程用于生成炎症得分并评估随时间变化.
主要成果:
- 炎症生物标志物的五个主要成分 (PC) 在痛风患者和基线对照之间存在显著差异.
- 与所有时间点的对照组相比,痛风患者的平均炎症评分显著更高.
- 与痛风患者的基线相比,ULT治疗导致24周和48周的炎症评分显著降低.
结论:
- 痛风的特点是独特的循环炎症生物标志物概况.
- 随着时间的推移,治疗到目标的ULT有效地减轻了痛风患者的全身炎症,使生物标志物模式更接近对照组的生物标志物模式.
- 这凸显了ULT在痛风管理中的重要性,无论是预防发作还是减少全身炎症.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
445
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
445
01:29Drugs for Treatment of Ulcerative Colitis in IBD
424
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
424
01:29Inflammatory Bowel Disease IV: Pharmacological Management
445
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
445
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
459
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
459
01:23Gastritis III: Clinical Manifestations and Management
1.1K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.1K
01:29Therapeutic Drug Monitoring: Affecting Factors
175
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
175